Northwestern University Archives • FRAXA Research Foundation

NKCC1 Inhibitor Bumetanide Corrects Synaptic and Circuit Hyperexcitability in Fragile X Mouse Model

FRAXA Research Foundation September 15, 2018February 7, 2020

Qionger He, PhD, and Anis Contractor, PhD

With $258,000 in grants since 2013 from FRAXA Research Foundation, Dr. Anis Contractor and Dr. Qionger He at Northwestern University are exploring the potential of the available drug bumetanide to correct altered GABA signalling in a mouse model of Fragile X syndrome.

Sleep and Circadian Rhythms in Fragile X Mutant Drosophila

FRAXA Research Foundation February 14, 2008August 5, 2021

Ravi Allada, MD, at Northwestern University, FRAXA research grant

With an $80,000 grant from FRAXA Research Foundation over 2 years, Dr. Ravi Allada and his team studied at Northwestern University sleep behaviors in Fragile X fruit flies. These fruit flies are useful for several important reasons; not only do they have a good cognitive phenotype, they also have a clear disturbance of circadian rhythms. This is an important model for human hyperactivity and sleep disorders, and this group studied the underlying mechanisms in an effort to find treatments for the human conditions.

Transport, Anchoring and Translation of FMRP-Associated mRNAs

FRAXA Research Foundation February 15, 2005August 13, 2018

Vladimir Gelfand, PhD, at Northwestern University, FRAXA research grant

With a $40,000 grant from FRAXA Research Foundation in 2005, Dr. Vladimir Gelfand and his team at Northwestern University studied the mechanisms of mGluR and mRNA and how it relates to FMRP.

Fragile X Syndrome and RNAi

FRAXA Research Foundation February 27, 2004March 21, 2019

With a $75,000 grant from FRAXA Research Foundation from 2003-2004, Dr. Richard Carthew and his team at Northwestern University studied their interest in gene expression by investigating the role of the recently discovered process of interfering RNA (RNAi). FMRP appears to be involved in the metabolism of RNAi, and may have a role in regulating the process; likewise, deficits in RNAi may contribute to the disease process in Fragile X.